AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Humalog has 41.3 points more BS than the average for Medical Devices, Pharma & Biotech.
Medical Devices, Pharma & Biotech BS: Humalog (humalog.com)
This is a digital ghost. The site provides zero substance and blocks forensic analysis, effectively operating as a high-authority domain with a low-authority soul.
Immediately remove the bot-challenge barrier for valid crawlers to allow for the indexing of critical medical information. Implement robust Organization and Product schema that links directly to FDA 510(k) or PMA approvals. Replace the empty homepage with high-density content including ‘indications for use,’ ‘clinical study citations,’ and ‘pharmacovigilance reporting mechanisms.’
The information density is non-existent with a char_count of 0 and zero headings detected. The site fails every metric for substance as it provides no specific nouns, technical protocols, or measurable outcomes. There is a 100% absence of specificity, earning maximum penalties for lack of evidence and substance ratio.
Parameter drift, trailing slash inconsistencies, and language leaks create unintended alternate identities. Get a Clinical Canonical Diagnosis to reveal where duplicate embeddings are silently created.
There is a total drift between the primary signal of the URL (a major insulin brand) and the actual delivered content, which is a generic ‘Just a moment…’ interstitial. No sub-pages were accessible to provide consistency, resulting in a complete disconnect between the brand’s global promise and the digital reality provided in the data. The heading hierarchy is entirely absent, providing no logical story or structure.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
The trust_theatre_flag is false only because no reviews are present to even falsify; however, the proof_links_count is 0, indicating a total lack of external validation paths. There are no links to clinical trials, FDA approval documents, or peer-reviewed studies as required by the industry dictionary. Any authority implied by the domain name is completely unsubstantiated within the provided evidence.
The ratio of verifiable evidence to claims is 0:0. In an industry where ‘clinical trial data’ and ‘pharmacovigilance’ are mandatory, the absolute absence of these elements across the crawled data points to a maximum bullshit score for transparency and proof.
To evaluate URL identity stability and multilingual coherence, review the Yoast Identity Stability audit. View the Yoast Identity Stability Audit for a practical example of canonical alignment and language layer integrity.
The site’s fingerprint is that of a generic technical gatekeeper rather than a medical authority. It fails to meet any ‘proof_expectations’ such as specific regulatory clearance numbers or GMP certification details. The value proposition is non-existent, and the page functions as a boilerplate template with zero unique positioning or industry-specific jargon.
There is a critical authority gap evidenced by the total lack of schema_json, Person schema, or Organization schema. No experts, healthcare professionals, or founders are named, leaving the site with zero verifiable digital footprint or technical credibility. The lack of structured data for a pharmaceutical entity claiming to be a major brand is a high-level BS signal.
While the site does not make explicit marketing claims in the text, its existence as the primary domain for a life-critical medical product without providing any indications for use or safety data is a major performance disconnect. The marketing tone is replaced by a technical void that fails to demonstrate any of the ‘breakthrough innovation’ expected in the pharma sector.
Medical Devices, Pharma & Biotech BS: Humalog (humalog.com)
The URL and industry classification suggest a pharmaceutical product for diabetes management, but the crawled data provides zero industry-specific content, instead returning a bot-challenge page. This creates a total vacuum where medical substance should be, confirming a failure to deliver on the expected industry signals.
The access layer decides whether your content even enters the model's world. Review the Crawlability & Indexation Framework to see how AI visible content differs from what humans see in the browser.
“The score is driven primarily by the 'insufficient' data flag and the total failure of Information Density (25/30) and Identity/Authority (15/15). The technical implementation prevents any measure of substance, leading to an extreme BS rating based on the distance between the brand's global reputation and this specific digital evidence.”
Analysis Disclosure & Source Attribution
Snapshot Date: May 30, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at Humalog to view the most current version of their content and see directly what the company offers.